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Abstract	
This	PhD	submission	presents	a	case	study	of	an	academic	group	working	as	
infomediaries	at	the	interface	between	research	and	global	policy,	and	at	the	
interface	between	global	policy	and	national	decisions:	advising	on	methodological	
issues,	conducting	systematic	evidence	reviews	in	response	to	information	needs,	
and	developing	approaches	for	reinterpreting	global	guidance	for	national	decision-
making.		
The	included	systematic	reviews	were	among	the	first	to	adopt	innovative	elements	
such	as:	summary	of	findings	tables,	standardized	language	reflecting	the	level	of	
certainty	in	effect	estimates,	logic	frameworks,	and	brief	economic	summaries;	and	
have	contributed	to	the	further	development	of	these	methods.	This	work	has	
helped	to	establish	formal	and	transparent	methods	within	global	malaria	guidance,	
and	contributed	to	improved	standards	in	global	guidance	more	broadly.	
						x	
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Chapter	1.	Developing	global	and	national	clinical	guidelines	
Introduction	
Over	the	past	20	years,	many	high-income	countries	have	recognized	the	value	of	
national	evidence-based	clinical	guidelines,	and	established	independent	bodies	to	
oversee	their	development	[15][16].	Clinical	guidelines	aim	to	improve	the	health	of	
populations	by	promoting	proven	treatments	and	raising	standards.	They	provide	a	
meaningful	basis	for	audit	of	clinical	practice	and	healthcare	provision,	and	
promote	the	rational,	cost-effective	use	of	resources,	such	as	medicines,	therapies	
and	laboratory	tests.	
While	the	autonomous	production	of	clinical	guidelines	by	individual	countries	is	
likely	to	promote	ownership	of	the	recommendations,	and	influence	dissemination	
and	implementation,	it	is	also	a	duplication	of	efforts,	and	potentially	wasteful	use	
of	resources.	Indeed,	the	cost	for	developing	a	clinical	guideline	following	current	
standards	is	substantial,	and	likely	to	be	prohibitive	for	most	low-	and	middle-
income	countries.	
As	such,	it	seems	important	to	establish	ways	of	reducing	duplication,	without	
reducing	ownership,	and	the	World	Health	Organization	(WHO)	and	the	Cochrane	
Collaboration	are	two	organizations	ideally	placed	to	facilitate	this	at	a	global	level	
[17].		
Current	standards	in	guideline	development	
Currently,	the	most	widely	used	system	for	developing	evidence-based	healthcare	
recommendations	is	the	‘Grading	of	Recommendations	Assessment,	Development	
and	Evaluation’	approach	(GRADE)	[18].	This	approach	was	developed	by	an	
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international	consensus	of	methodologists	in	response	to	the	diverse	collection	of	
unsatisfactory	systems	in	use	in	the	early	2000s	[19].		
Crucially,	the	GRADE	working	group	recognized	that	evidence	of	intervention	
effects	was	not	sufficient	to	guide	recommendations,	and	inevitably	a	number	of	
further	judgments	are	required.	The	GRADE	approach	therefore	separates	the	
appraisal	of	the	‘quality	of	the	evidence’	(see	figure	1)	from	the	‘strength	of	the	
recommendation’	(see	figure	2)	[20][21].	
Figure	1:	The	GRADE	approach	to	rating	the	quality	of	evidence.	Adapted	from	Guyatt	2008.	[20]	
	
Figure	2:	The	GRADE	approach	to	defining	the	strength	of	a	recommendation.	Adapted	from	Guyatt	2008.	[21]	
	
The	GRADE	approach	defines	‘quality’	as	the	extent	to	which	we	can	be	confident	that	the	
estimates	of	effect	are	correct.	Four	levels	of	‘quality’	are	used.	Evidence	from	randomized	
controlled	studies	is	initially	graded	as	HIGH	and	downgraded	by	one,	two,	or	three	levels	after	
full	consideration	of:	any	limitations	in	the	design	of	the	studies,	the	directness	(or	
applicability)	of	the	evidence,	and	the	consistency	and	precision	of	the	results.		
High:		 Further	research	is	very	unlikely	to	change	our	confidence	in	the	estimate	of	
effect.	
Moderate:	 Further	research	is	likely	to	have	an	important	impact	on	our	confidence	in	the	
estimate	of	effect	and	may	change	the	estimate.	
Low:	 Further	research	is	very	likely	to	have	an	important	impact	on	our	confidence	in	
the	estimate	of	effect	and	is	likely	to	change	the	estimate.		
Very	Low:		 We	are	very	uncertain	about	the	estimate.	
	
The	GRADE	approach	defines	two	strengths	of	recommendations:	‘strong’	and	‘weak’	(or	
‘conditional’).	The	strength	of	recommendation	is	influenced	by	consideration	of:	the	quality	of	
evidence,	the	relative	balance	of	benefits	and	harms,	patient	values	and	preferences,	cost	and	
resource	requirements,	acceptability	and	feasibility.	
	 For	patients	 For	clinicians	 For	policy	makers	
Strong:	 Most	people	in	your	
situation	would	want	the	
recommended	course	of	
action	and	only	a	small	
proportion	would	not.	
Most	patients	should	receive	
the	recommended	course	of	
action.		
	
The	recommendation	
can	be	adopted	as	
policy	in	most	
situations.		
	
Weak:		 Many	people	in	your	
situation	would	want	the	
recommended	course	of	
action,	but	also	many	
would	not.		
	
Each	patient	should	be	
provided	with	sufficient	
information	to	arrive	at	their	
own	decision,	consistent	with	
their	values	and	preferences.	
Policy-making	at	the	
local	level	will	
require	substantial	
debate	among	
stakeholders.		
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To	be	truly	useful	to	their	target	audience,	clinical	guidelines	also	need	to	be	free	
from	bias,	well	presented,	and	user-friendly.	The	Appraisal	of	Guidelines	for	
Research	and	Evaluation	Instrument	(AGREEII)	was	first	published	in	2003,	and	lays	
out	the	elements	of	a	good	guideline.	It	provides	a	framework	for	documenting	the	
guideline	process,	and	can	be	used	to	appraise	the	quality	of	clinical	guidelines	
against	an	international	standard	(see	figure	3)[22].		
Figure	3:	The	six	domains	of	the	AGREEII	Instrument	for	appraising	the	quality	of	healthcare	guidelines.	
Adapted	from	Brouwers	2010.	[22]	
	
The	role	of	the	Cochrane	Collaboration	
Systematic	reviews	are	a	key	step	in	ensuring	that	clinical	recommendations	are	
based	on	empirical	evidence.	Following	pre-specified	protocols,	researchers	search	
for,	collate,	and	appraise	all	the	available	primary	research	appropriate	to	
answering	current	clinical	questions	[23].					
The	Cochrane	Collaboration	has	been	a	major	player	in	the	development	of	
systematic	review	methods	and	remains	a	leading	producer	of	systematic	reviews	
worldwide	[24].	Since	its	inception	the	collaboration	has	emphasized	the	need	to	be	
independent,	and	free	from	commercial,	financial	and	academic	conflicts	of	interest	
[25].	As	the	name	suggests,	it	encourages	collaboration	rather	than	competition,	
Scope	and	purpose:	 The	description	of	the	overall	aim	of	the	guideline,	the	scope	of	
the	questions,	and	the	target	audience.	
Stakeholder	involvement:	 The	appropriate	involvement	of	all	stakeholders,	including	the	
intended	users	and	beneficiaries	of	the	guideline.	
Rigour	of	development:	 The	methods	used	to	search	for,	synthesize,	and	appraise	
evidence,	formulate	recommendations,	and	keep	them	
updated.	
Clarity	of	presentation:	 The	general	language,	structure,	and	format	of	the	guideline.	
Applicability:	 Discussion	of	the	barriers	and	facilitators	to	implementation,	
and	advice	or	tools	to	improve	uptake	and	implementation.	
Editorial	independence:	 The	methods	used	to	declare	and	manage	potential	conflicts	of	
interest	related	to	the	funding	body	or	the	guideline	group	
members.	
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bringing	together	multinational	authorship	teams.	The	most	common	type	of	
Cochrane	review	assesses	the	benefits	and	harms	of	a	particular	treatment	or	
intervention,	but	a	full	guideline	process	may	also	require	systematic	reviews	on	
disease	prognosis,	diagnostic	test	accuracy,	or	patient	experience	and	preferences	
[26].	
Typically	a	Cochrane	systematic	review	includes	and	appraises	the	global	evidence-
base	regardless	of	language.	However,	for	many	interventions,	the	benefits	and	
harms	that	can	be	expected	will	be	modified	by	contextual	factors	such	as	disease	
prevalence	and	virulence,	population	age,	sex,	lifestyle,	and	genetics.	Systematic	
reviews	conducted	at	the	global	level	will	therefore	only	be	useful	at	the	national	
and	local	levels	if	they	present	this	information	clearly	to	the	reader	and	adequately	
explore	the	nature	of	the	effect	modification	[27].		
The	role	of	the	World	Health	Organization	
It	follows	from	the	GRADE	separation	of	‘quality	of	evidence’	from	‘strength	of	
recommendation’	that	even	when	the	global	evidence-base	is	broadly	applicable,	
policy	makers	in	different	settings	may	make	different	decisions	[21][28].	Local	
priorities,	local	health	system	resources,	and	cultural	variation	in	values	and	
preferences	all	influence	if,	where,	and	how	much	of	a	particular	intervention	
should	be	implemented.	So	what	then	is	the	role	of	the	WHO	as	a	producer	of	
global	guidance?	
One	traditional	role	has	been	for	the	WHO	to	provide	guidance	for	use	in	countries	
with	little	local	capacity	to	develop	their	own.	In	this	role,	WHO	guidelines	may	be	
targeted	directly	at	local	implementers	(such	as	clinical	staff),	and	bypass	local	
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decision-making	processes.	This	paternalistic	approach,	though	necessary	at	times,	
risks	being	biased	by	global	priorities,	and	ignorant	of	local	insight.		
As	capacity	in	many	low-	and	middle-income	countries	increases,	it	is	likely	that	this	
role	will	diminish	with	national	ministries	demanding	greater	control	over	their	own	
priorities	and	resources.	As	such,	the	WHO	may	be	required	to	re-align	itself	as	a	
facilitator	of	autonomous	national	decision-making;	setting	a	framework	for	global	
disease	control,	and	providing	synthesized	evidence	on	effects,	cost,	and	feasibility	
for	consideration	of	individual	decisions	at	the	national	level.	In	doing	so,	the	
primary	audience	for	WHO	documents	would	need	to	shift	from	local	implementers	
to	local	policy	makers.		
The	aim	and	scope	of	this	PhD	submission	
I	have	been	part	of	the	WHO	Malaria	Treatment	Guidelines	(MTG)	committee	since	
2007,	initially	as	a	technical	advisor	(presenting	my	systematic	reviews	of	anti-
malarial	drug	efficacy),	and	later	as	a	guideline	methodologist	–	with	input	into	the	
guideline	process	and	document	format.	While	the	main	focus	of	all	three	editions	
has	been	the	drug	treatment	of	malaria	illness,	some	recommendations	are	also	
made	around	malaria	diagnosis	and	prevention	[29][30][31].	
The	primary	aim	of	the	included	papers	was	to	ensure	that	malaria	
recommendations	made	at	the	global	level	were	informed	by	reliable	summaries	of	
the	available	evidence-base.	Through	the	course	of	the	work	I	have	become	
interested	in	how	the	global	evidence-base	and	global	recommendations	are	then	
utilized	by	national	policy	makers.			
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Chapters	2	and	3	present	systematic	reviews	of	anti-malarial	drug	efficacy	for	the	
treatment	of	uncomplicated	(non-severe)	malaria	and	severe	malaria	respectively,	
and	chapter	4	presents	a	systematic	review	of	the	effects	of	introducing	rapid	
diagnostic	tests	in	areas	without	access	to	light	microscopy.	These	reviews	were	
used	to	inform	the	recommendations	of	the	second	and	third	editions	of	the	WHO	
Malaria	Treatment	Guidelines.		
Chapter	5	presents	a	formal	appraisal	of	the	quality	of	WHO	guidelines,	alongside	a	
demonstration	project	utilizing	and	re-interpreting	global	guidance	at	the	national	
level.	
In	chapter	6,	I	discuss	my	overall	conclusions	about	the	implications	for	guideline	
development	at	the	World	Health	Organization,	and	in	low-	and	middle-income	
countries.	
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Chapter	2.	Which	first-line	treatment	for	uncomplicated	malaria?	
Main	paper	
Sinclair	D,	Zani	B,	Donegan	S,	Olliaro	P,	Garner	P.	Artemisinin-based	combination	
therapy	for	treating	uncomplicated	malaria.	Cochrane	Database	of	Systematic	
Reviews.	2009;	Issue	3.	[1]	
Additional	contributing	work	
Zani	B,	Gathu	M,	Donegan	S,	Olliaro	PL,	Sinclair	D.	Dihydroartemisinin-piperaquine	
for	treating	uncomplicated	P.	falciparum	malaria.	Cochrane	Database	of	Systematic	
Reviews.	2014;	Issue	1.	[6]	
Bukirwa	H,	Unnikrishnan	B,	Kramer	CV,	Sinclair	D,	Nair	S,	Tharyan	P.	Artesunate	plus	
pyronaridine	for	treating	uncomplicated	Plasmodium	falciparum	malaria.	Cochrane	
Database	of	Systematic	Reviews.	2014;	Issue	3.	[7]	
Isba	R,	Zani	B,	Gathu	M,	Sinclair	D.	Artemisinin-naphthoquine	for	treating	
uncomplicated	Plasmodium	falciparum	malaria.	Cochrane	Database	of	Systematic	
Reviews.	2015;	Issue	2.	[8]	
Sinclair	D,	Gogtay	N,	Brand	F,	Olliaro	PL.	Artemisinin-based	combination	therapy	for	
treating	uncomplicated	Plasmodium	vivax	malaria.	Cochrane	Database	of	
Systematic	Reviews.	2011;	Issue	7.	[9]	
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Background	
The	first	edition	of	the	WHO	Malaria	Treatment	Guidelines	endorsed	‘combination	
therapy’	as	a	global	strategy	for	malaria	treatment	[29].	The	development	and	
spread	of	anti-malarial	resistance	had	rendered	most	older	mono-therapies	
obsolete,	and	the	panel	considered	combination	therapy	essential	to	protect	new	
anti-malarials	against	further	resistance	[32].	This	policy	mirrored	similar	
approaches	in	tuberculosis	and	HIV,	and	emerged	at	the	time	when	artemisinin-
based	combination	therapies	(ACTs)	were	being	developed.		
In	2006	the	WHO	formally	recommended	four	ACTs:	artesunate	plus	mefloquine,	
artemether-lumefantrine,	artesunate	plus	amodiaquine,	and	artesunate	plus	
sulfadoxine-pyrimethamine;	and	one	non-artemisinin-based	combination	still	
available	and	used	in	several	countries:	amodiaquine	plus	sulfadoxine-
pyrimethamine	[29].		
By	the	time	of	the	second	edition,	however,	national	malaria	programmes	were	
asking	the	WHO	for	more	guidance	on	how	to	select	their	national	first-line	
treatment,	and	consequently	we	undertook	a	systematic	review	to	summarize	the	
relative	benefits	and	harms	of	the	five	recommended	combinations	and	one	new	
combination	which	had	shown	promise	in	recent	trials:	dihydroartemisinin-
piperaquine.		
While	several	Cochrane	reviews	had	already	synthesized	the	evidence	around	
individual	ACT	comparisons	[33][34][35][36],	this	review	aimed	to	provide	all	
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relevant	head-to-head	comparisons	within	a	single	review,	and	allow	policy	makers	
to	directly	compare	the	relative	benefits	and	harms	of	each	option.	
	
Policy	question	
What	are	the	relative	benefits	and	harms	of	the	recommended	ACTs?	
Methods	
We	followed	standard	Cochrane	methods	to	formulate	the	key	questions,	construct	
a	protocol,	and	then	formally	search	for,	and	appraise,	all	randomized	head-to-head	
trials	of	ACTs	in	uncomplicated	P.	falciparum	malaria.		
To	facilitate	appropriate	meta-analysis,	we	needed	to	standardize	the	way	losses-
to-follow-up	and	missing	data	were	handled	across	all	trials.	Our	primary	analysis	
therefore	followed	the	WHO's	protocol	for	assessing	and	monitoring	anti-malarial	
drug	efficacy	[37][38].	This	protocol	describes	a	complete	case	analysis,	which	
excludes	all	participants	with	incomplete	or	missing	outcome	data	from	the	efficacy	
estimate.	To	test	the	robustness	of	this	approach,	we	then	conducted	a	series	of	
sensitivity	analyses,	which	aimed	to	restore	the	integrity	of	the	randomization	
process	(see	figure	4).	
Our	primary	outcome	was	treatment	failure,	defined	as	the	presence	of	recurrent	
parasitaemia	during	the	period	of	follow-up,	with	Polymerase	Chain	Reaction	(PCR)	
genotyping	used	to	adjust	this	result	to	exclude	probable	new	infections	[39].	
Secondary	outcomes	were	parasite	and	fever	clearance	during	the	first	week,	
gametocyte	clearance,	anaemia,	and	adverse	effects.	
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We	used	the	GRADE	approach	to	evaluate	the	quality	of	evidence,	and	presented	
the	effect	estimates	for	the	main	outcomes	alongside	the	GRADE	judgments	in	
summary	of	findings	tables.	
Figure	4:	A	standardized	approach	to	handling	missing	data	across	trials.	Developed	from	Bloland	2003.	[37]	
Analysis	 Participants	 PCRa-unadjusted	 PCR-adjusted	
Numerator	 Denominator	 Numerator	 Denominator	
Primary	
analysis	
Exclusions	after	
enrolment	
Excludedb	 Excluded	 Excluded	 Excluded	
Missing	or	
indeterminate	
PCR	
Included	as	
failures	
Included	 Excluded	 Excluded	
New	infections	 Included	as	
failures	
Included	 Excluded	 Excluded	
Sensitivity	
analysis	1c	
As	'Primary	
analysis'	except:	
missing	or	
indeterminate	
PCR	
—	 —	 Included	as	
failures	
Included	
Sensitivity	
analysis	2d	
As	'Sensitivity	
analysis	1'	except:	
new	infections	
—	 —	 Included	as	
successes	
Included	
Sensitivity	
analysis	3e	
As	'Sensitivity	
analysis	2'	except:	
exclusions	after	
enrolment	
Included	as	
failures	
Included	 Included	as	
failures	
Included	
Sensitivity	
analysis	4f	
As	'Sensitivity	
analysis	2'	except:	
exclusions	after	
enrolment	
Included	as	
successes	
Included	 Included	as	
successes	
Included	
Note:	participants	who	were	found	not	to	satisfy	the	inclusion	criteria	after	randomization	are	
removed	from	all	calculations.	
a	PCR:	polymerase	chain	reaction.	
b	'Excluded'	means	removed	from	the	calculation.	
c	To	re-classify	all	indeterminate	or	missing	PCR	results	as	treatment	failures	in	the	PCR-adjusted	
analysis.	
d	To	re-classify	all	PCR-confirmed	new	infections	as	treatment	successes	in	the	PCR-adjusted	analysis.	
(This	analysis	may	overestimate	efficacy	as	PCR	is	not	wholly	reliable	and	some	recrudescences	may	
be	falsely	classified	as	new	infections.	Also	some	participants	may	have	gone	on	to	develop	a	
recrudescence	after	the	new	infection.)	
e	To	re-classify	all	exclusions	after	enrolment	(losses	to	follow-up,	withdrawn	consent,	other	anti-
malarial	use,	or	failure	to	complete	treatment)	as	treatment	failures.	For	PCR-unadjusted	total	
failure	this	represents	a	true	worst-case	scenario.	
f	To	re-classify	all	exclusions	after	enrolment	(losses	to	follow-up,	withdrawn	consent,	other	anti-
malarial	use,	or	failure	to	complete	treatment)	as	treatment	successes.	
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Key	findings	
Fifty	studies	met	the	inclusion	criteria,	with	most	conducted	between	2003	and	
2009.	Thirty-one	trials	were	conducted	in	Africa,	17	in	Asia,	one	in	South	America,	
and	one	in	Oceania.	Pregnant	and	lactating	women	were	excluded	from	all	trials.	
The	study	populations	in	Asian	trials	were	older,	with	exclusion	of	children	aged	less	
than	one	year,	while	African	studies	concentrated	on	children	including	those	as	
young	as	six	months.	
All	five	ACTs	achieved	PCR-adjusted	failure	rates	of	less	than	10%,	in	line	with	the	
WHO	recommended	standard	(established	by	consensus	in	the	first	edition	of	the	
guidelines),	at	most	study	sites.	
The	new	ACT,	dihydroartemisinin-piperaquine,	performed	well	compared	to	the	
most	commonly	used	drugs	in	specific	settings:	versus	artesunate	plus	mefloquine	
in	Asia	(PCR-adjusted	treatment	failure:	RR	0.39,	95%	CI	0.19	to	0.79;	three	trials,	
1062	participants);	and	versus	artemether-lumefantrine	in	Africa	(RR	0.39,	95%	CI	
0.24	to	0.64;	three	trials,	1136	participants)	(see	figure	5).	
Artesunate	plus	mefloquine	performed	well	in	trials	from	Asia	and	South	America,	
with	failure	rates	consistently	low,	but	was	rarely	studied	in	the	African	context.		
Artemether-lumefantrine	and	artesunate	plus	amodiaquine	performed	well	in	
almost	all	studies	they	were	involved	in	but	single	trials	from	Uganda	found	failure	
rates	in	excess	of	10%.		
Amodiaquine	plus	sulfadoxine-pyrimethamine	performed	poorly	in	East	Africa	
versus	artemether-lumefantrine	(RR	0.12,	95%	CI	0.06	to	0.24;	two	trials,	618	
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participants),	and	versus	artesunate	plus	amodiaquine	(RR	0.44,	95%	CI	0.22	to	
0.89;	three	trials,	1515	participants).	
Figure	5:	Forest	plot	of	randomized	trials,	comparing	dihydroartemisinin-piperaquine	(DHA-P)	against	all	
comparators,	for	the	primary	outcome:	PCR-adjusted	treatment	failure	at	the	longest	available	time-point.	
Taken	from	Sinclair	2009.	[1]	
	
Strengths	and	limitations	of	this	approach	
Systematic	reviews	are	not	always	welcomed	by	disciplines	new	to	their	use,	and	
within	infectious	diseases	some	prominent	figures	had	expressed	skepticism	about	
the	approach	due	to	expected	variability	in	drug	effects	over	time	and	place	
associated	with	drug	resistance.	It	was	therefore	critical	that	this	review	fully	
considered	this	heterogeneity	in	its	analysis	and	conclusions.	
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To	facilitate	this,	we	made	several	modifications	to	the	standard	presentation	of	
forest	plots	(see	figure	5):	
• A	three-letter	country	code	denoting	the	trial	setting	was	added	to	each	
study	ID,	
• The	year	each	study	finished	recruitment	was	added	in	the	final	data	
column,	
• Within	each	sub-group,	trials	were	arranged	chronologically	with	oldest	
trials	first.	
These	modifications	allowed	readers	to	make	their	own	assessments	of	applicability	
and	declining	efficacy	over	time,	and	facilitated	our	investigation	of	heterogeneity	
through	sub-group	analyses	by	time	and	place.	
When	drawing	conclusions	about	the	applicability	of	results,	it	was	then	important	
to	consider	how	the	known	resistance	pattern	of	each	partner	drug	might	influence	
where	trials	were	conducted.	It	seemed	likely	to	us	that	the	equipoise	required	to	
ethically	justify	a	randomized	trial	could	restrict	the	evaluation	of	specific	ACTs	in	
settings	with	documented	resistance,	and	we	found	some	evidence	of	this	with	
artesunate	plus	sulfadoxine-pyrimethamine.	In	our	analyses	this	combination	
performed	well	against	other	ACTs	but	the	number	of	trial	settings	was	severely	
limited	(with	widespread	resistance	to	sulfadoxine-pyrimethamine	in	most	of	
Africa).	As	a	consequence	we	noted	that	systematic	reviews	are	unlikely	to	detect	
declining	efficacy	of	anti-malarials	over	time,	and	alternative	methods	will	be	
required	to	justify	withdrawal	of	recommended	drugs,	such	as	single-arm	efficacy	
studies,	or	in-vitro	monitoring	of	known	markers	of	resistance	[40].	
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More	positively,	knowledge	of	the	known	resistance	patterns	can	permit	
generalization	of	results	to	additional	settings	beyond	those	of	the	included	trials.	
For	example,	in	this	version	of	the	review,	there	were	no	African	studies	evaluating	
artesunate-mefloquine	(due	to	historical	concerns	about	mefloquine	causing	
excessive	vomiting	in	children).	However,	as	mefloquine	resistance	has	not	been	
documented	in	Africa	it	is	highly	likely	that	this	combination	will	be	effective	even	
without	local	trials.		
Following	publication	of	the	review,	and	the	subsequent	recommendation	in	favour	
of	dihydroartemisinin-piperaquine,	the	European	Medicines	Agency	(EMA)	raised	
concerns	about	potential	cardio-toxicity	with	this	combination	[41].	Our	review	had	
found	few	signals	of	major	safety	concerns,	but	this	was	primarily	due	to	
inadequate	safety	monitoring	in	the	underlying	trials,	and	consequently	insufficient	
to	be	reassuring	to	those	making	decisions.	None	of	the	included	trials	had	
conducted	ECG	monitoring	of	participants,	but	two	randomized	controlled	trials	
(RCTs)	published	after	the	Cochrane	review	had	noted	an	increased	risk	of	QT	
prolongation	in	those	treated	with	dihydroartemisinin-piperaquine.			
Given	the	high	efficacy	of	the	recommended	ACTs,	the	adverse	event	profile	
became	a	critical	consideration	for	national	policy	makers	when	selecting	first-line	
treatments.	Consequently,	for	subsequent	reviews	of	individual	anti-malarial	
combinations	we	developed	a	new	approach	to	assessing	and	documenting	the	
adequacy	of	adverse	event	monitoring	and	completeness	of	reporting,	and	
produced	detailed	adverse	event	summary	of	findings	tables,	detailing	the	absolute	
risk	of	adverse	events	and	the	confidence	in	those	estimates	(see	figure	6).	
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Figure	6:	Summary	of	findings	table	for	adverse	events	with	dihydroartemisinin-piperaquine	versus	
artemether-lumefantrine.	Adapted	from	Zani	2014.	[6]		
Patient	or	population:	Patients	with	uncomplicated	P.	falciparum	malaria	
Settings:	Malaria	endemic	areas	
Intervention:	Dihydroartemisinin-piperaquine	(DHA-P)	
Comparison:	Artemether-lumefantrine	(AL6)	
Outcomes	 Number	of	participants	
having	adverse	events	
(95%	CI)	
Number	of	
participants	
(trials)	
Quality	of	the	
evidence	
(GRADE)	
AL6	 DHA-P	
Serious	adverse	events		
(including	deaths)	
6	per	1000	 10	per	1000	
(6	to	17)	
7022	
(8	trials)	
moderate1,2,3,4	
Gastroenterological	 Early	
vomiting	
2	per	100	 3	per	100	
(2	to	5)	
2695	
(3	trials)	
moderate2,3,5,6	
Vomiting	 9	per	100	 9	per	100	
(8	to	11)	
6761	
(9	trials)	
moderate2,3,5,6	
Nausea	 2	per	100	 2	per	100	
(1	to	7)	
547	
(2	trials)	
low2,3,5,7	
Diarrhoea	 12	per	100	 12	per	100	
(10	to	14)	
4889	
(7	trials)	
moderate2,3,5,6	
Abdominal	
pain	
19	per	100	 16	per	100	
(12	to	20)	
911	
(5	trials)	
low2,3,5,8	
Anorexia	 15	per	100	 14	per	100	
(12	to	17)	
3834	
(5	trials)	
moderate2,3,5,6	
Neuro-psychiatric	 Headache	 27	per	100	 33	per	100	
(25	to	44)	
309	
(2	trials)	
low2,3,5,8	
Sleeplessness	 1	per	100	 3	per	100	
(1	to	9)	
547	
(2	trials)	
low2,3,5,7	
Dizziness	 3	per	100	 4	per	100	
(2	to	11)	
547	
(2	trials)	
low3,5,7	
Sleepiness	 0	per	100	 0	per	100	
(0	to	0)	
384	
(1	trial)	
low2,3,5,7	
Weakness	 17	per	100	 18	per	100	
(15	to	21)	
1812	
(5	trials)	
moderate2,3,5,6	
Cardio-respiratory	 Cough	 42	per	100	 42	per	100	
(40	to	45)	
4342	
(5	trials)	
moderate2,3,5,6	
Coryza	 68	per	100	 66	per	100	
(60	to	72)	
832	
(2	trials)	
low1,2,3,8	
Prolonged	
QT	interval	
(Bazett's	
correction)	
7	per	100	 9	per	100	
(6	to	11)	
1548	
(1	trial)	
low5,8,11	
Prolonged	
QT	interval	
(Fridericia's	
correction)	
0	per	100	 0	per	100	
(0	to	2)	
1548	
(1	trial)	
low5,8,11	
Musculoskeletal/	
dermatological		
Pruritus	 2	per	100	 4	per	100	
(2	to	6)	
2033	
(5	trials)	
moderate2,3,5,6	
Facial	
oedema	
0	per	100	 0	per	100	
(0	to	0)	
384	
(1	trial)	
low2,3,5,7	
The	assumed	risk	of	adverse	events	in	the	AL6	group	is	an	average	risk	across	trials.	The	
corresponding	risk	with	DHA-P	(and	its	95%	CI)	is	based	on	the	assumed	risk	in	the	comparison	
group	and	the	relative	effect	of	the	intervention	(and	its	95%	CI).	
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CI:	Confidence	interval;	RR:	Risk	ratio.	
1	No	serious	risk	of	bias:	All	but	one	of	the	trials	are	open	label.	However,	we	did	not	down	grade	for	
this	outcome.	
2	No	serious	inconsistency:	The	finding	is	consistent	across	all	trials.	Statistical	heterogeneity	is	low.	
3	No	serious	indirectness:	Trials	were	mainly	conducted	in	children	in	Africa,	with	few	trials	in	Asia	or	
in	adults.	
4	Downgraded	by	1	for	serious	imprecision:	No	statistically	significant	difference	was	detected	
between	treatments.	However	the	current	sample	size	does	not	exclude	the	possibility	of	rare	but	
clinically	important	differences.	
5	Downgraded	by	1	for	risk	of	bias:	The	majority	of	trials	are	open	label.	
6	No	serious	imprecision:	The	finding	is	of	no	effect	and	the	CIs	around	the	absolute	effect	excludes	
clinically	important	differences.	
7	Downgraded	by	1	for	serious	imprecision:	There	are	limited	data.	
8	Downgraded	by	1	for	serious	imprecision:	The	result	does	not	reach	statistical	significance.	
9	No	serious	imprecision:	The	total	number	of	participants	is	high	and	findings	are	precise.	
10	Downgraded	by	1	for	serious	risk	of	bias:	This	trial	is	unblinded.	Only	a	few	of	the	recorded	
prolonged	QT	intervals	were	registered	as	adverse	events	which	removed	the	statistical	significance.	
The	reasons	for	this	are	unclear.	
11	No	serious	indirectness:	This	single	trial	was	conducted	in	children	in	Uganda,	Kenya,	
Mozambique,	Zambia,	and	Burkina	Faso.	
	
Influence	on	WHO	recommendations		
The	WHO	formally	considered	the	first	draft	of	the	review	in	2008.	This	was	the	first	
time	the	WHO	malaria	department	had	utilized	the	GRADE	approach	to	formulating	
recommendations,	and	a	GRADE	sub-group	was	formed	to	learn	the	methodology	
and	formally	go	through	the	evaluations	of	‘quality	of	evidence’.	Following	
discussions,	the	committee	added	dihydroartemisinin-piperaquine	to	the	list	of	
recommended	ACTs,	and	withdrew	the	recommendation	for	amodiaquine	plus	
sulfadoxine-pyrimethamine.	
This	process	established	a	transparent	and	systematic	approach	to	the	evaluation	
and	consideration	of	new	anti-malarial	combinations,	and	for	the	third	edition	in	
2015	we	utilized	the	same	protocol	and	several	new	review	teams	to	develop	three	
further	Cochrane	reviews	in	response	to	current	questions:	
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• ‘Dihydroartemisinin-piperaquine	for	treating	uncomplicated	P.	falciparum	
malaria’.	Following	the	EMA	report,	the	WHO	committee	formally	
considered	the	evidence	for	cardio-toxicity	with	dihydroartemisinin-
piperaquine,	and	concluded	with	a	strong	recommendation	in	favour	of	
dihydroartemisinin-piperaquine	(Strong	recommendation,	high	quality	
evidence).		
• ‘Artesunate	plus	pyronaridine	for	treating	uncomplicated	P.	falciparum	
malaria’.	Prior	to	the	WHO	meeting,	some	expected	this	new	combination	
would	be	added	to	the	list	of	recommended	drugs.	However,	the	review	
highlighted	the	lack	of	data	in	children,	and	the	concerns	about	liver	toxicity.	
The	committee	therefore	did	not	recommend	artesunate-pyronaridine	for	
general	use,	but	made	allowance	for	its	use	in	settings	with	resistance	to	
other	combinations	(Conditional	recommendation,	moderate	quality	
evidence).	
• ‘Artemisinin-naphthoquine	for	treating	uncomplicated	P.	falciparum	
malaria’.	Although	there	was	some	pressure	from	the	pharmacological	
company	for	the	WHO	to	consider	this	combination,	the	review	highlighted	
that	very	little	data	was	available	and	provided	justification	for	the	panel	not	
to	recommend	it	(Strong	recommendation,	very	low	quality	evidence).		
A	variation	of	this	review	was	also	used	to	assess	the	use	of	artemisinin-based	
combination	therapies	in	the	treatment	of	Plasmodium	vivax	malaria,	and	this	was	
also	presented	and	considered	by	the	panel.	
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Chapter	3.	Which	first-line	treatment	for	severe	malaria?	
Main	paper	
Sinclair	D,	Donegan	S,	Isba	R,	Lalloo	DG.	Artesunate	versus	quinine	for	treating	
severe	malaria.	Cochrane	Database	of	Systematic	Reviews.	2012;	Issue	6.	[2]	
Additional	contributing	work	
Asare	B,	Sinclair	D.	Evidence	summary	for	artesunate	[10]	
Buabin	D,	Mensah	NO,	Sinclair	D.	Evidence	summary	for	artemether.	[11]	
(On-line	appendices	to:	Sinclair	D,	Gyansa-Lutterodt	M,	Asare	B,	Koduah	A,	
Andrews	E,	et	al.	Integrating	global	and	national	knowledge	to	select	medicines	for	
children:	The	Ghana	National	Drugs	Programme.	PLoS	Med.	2013;10(5):e1001449.).	
[5]	
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Background	
Many	deaths	from	severe	malaria	occur	during	the	first	24	to	48	hours	following	
hospital	admission	and,	consequently,	to	be	effective	anti-malarial	drugs	need	to	
achieve	rapid	therapeutic	blood	concentrations	following	administration	[42].		
The	artemisinin	derivatives	have	been	shown	to	clear	malaria	parasites	from	the	
blood	faster	than	other	anti-malarials	[43][44],	and	importantly	they	are	also	more	
effective	against	the	young	ring	forms	of	the	parasite,	which	sequester	in	the	
microcirculation	of	vital	organs	causing	severe	disease	[42].	Artesunate	is	the	most	
studied	artemisinin	derivative,	and	was	first	recommended	in	the	second	edition	
WHO	Malaria	Treatment	Guidelines.		
Figure	7:	Evidence	box	in	support	of	the	WHO	recommendation	to	use	artesunate	in	preference	to	quinine	in	
adults	with	severe	malaria.	Taken	from	the	WHO	Malaria	Treatment	Guidelines:	Second	edition.	[30]	
	
At	that	time	an	earlier	version	of	the	Cochrane	review	was	used	as	the	basis	for	
GRADE	evidence	profiles	presented	to	the	guideline	panel	[45].	After	consideration	
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of	the	evidence	the	WHO	recommended	artesunate	for	use	in	adults,	but	concluded	
there	was	insufficient	evidence	to	make	recommendations	about	its	use	in	children	
(see	Figure	7).		
In	2010	we	conducted	an	update	of	the	review,	to	include	newly	published	trials	in	
children,	and	in	2012	we	added	an	appraisal	and	commentary	on	cost-effectiveness	
studies.		
Policy	question	
Does	parenteral	artesunate	reduce	deaths	from	malaria	compared	to	parenteral	
quinine	in	children?		
Methods	
We	used	standard	Cochrane	methods	to	formally	search	for,	appraise,	and	
synthesize	randomized	controlled	trials	comparing	intravenous	or	intramuscular	
artesunate	with	intravenous	or	intramuscular	quinine,	in	adults	and	children	with	
severe	malaria.	The	primary	outcome	was	death,	and	secondary	outcomes	were:	
neurological	sequelae,	coma	recovery	time,	time	to	hospital	discharge,	fever	
clearance	time,	parasite	clearance	time,	and	adverse	effects.	
This	was	the	first	systematic	review	by	the	Cochrane	Infectious	Diseases	Group	to	
use	the	GRADE	approach	to	evaluate	the	quality	of	evidence.	We	used	the	following	
considerations	to	assist	our	judgments:	
• Risk	of	bias:	we	conducted	sensitivity	analyses	to	assess	the	robustness	of	
the	results	against	the	risk	of	bias	criteria.		
• Consistency:	we	assessed	the	consistency	in	the	size	and	direction	of	the	
individual	effect	estimates,	and	the	overlap	of	the	confidence	intervals	of	
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individual	studies.	We	further	assessed	this	statistically	by	applying	the	Chi2	
test	and	the	I2	statistic.	To	explore	possible	causes	of	heterogeneity	we	
conducted	the	sub-group	analyses	described	below.	
• Directness:	we	evaluated	the	directness	and	applicability	of	the	results	by	
conducting	sub-group	analyses	by:	participant	age	(children	versus	adults),	
type	of	severe	malaria	(cerebral	versus	non-cerebral	malaria),	geographical	
region,	drug	regimen	(loading	dose	versus	no	loading	dose	of	quinine,	and	
use	of	any	additional	anti-malarials),	route	of	administration	(intravenous	
versus	intramuscular	route),	and	time	since	admission	to	hospital.		
• Precision:	we	considered	the	clinical	importance	of	the	upper	and	lower	
limits	of	the	95%	confidence	interval,	and	the	power	of	the	individual	
studies	and	overall	meta-analysis	to	detect	effects.	
• Publication	bias:	we	used	funnel	plots	to	consider	whether	we	had	any	
evidence	that	publication	bias	was	adversely	influencing	the	result.	
We	presented	the	effect	estimates	for	the	main	outcomes	alongside	the	GRADE	
judgments	in	summary	of	findings	tables.	
Key	findings	
We	found	eight	trials	enrolling	1664	adults	and	5765	children.	Six	trials	were	
conducted	in	Asia	and	two	in	Africa.	Of	these,	two	were	large	multicentre	studies:	
Dondorp	2005	[46],	11	centres	in	four	countries	(Bangladesh,	Myanmar,	India,	and	
Indonesia);	and	Dondorp	2010	[47],	11	centres	in	nine	countries	(Mozambique,	The	
Gambia,	Ghana,	Kenya,	Tanzania,	Nigeria,	Uganda,	Rwanda,	and	the	Democratic	
Republic	of	the	Congo).		
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Dondorp	2005	and	Dondorp	2010	used	rapid	diagnostic	tests	(RDTs)	to	confirm	P.	
falciparum	parasitaemia,	and	all	the	other	trials	used	standard	microscopy.	
Although	standardized	clinical	definitions	for	severe	malaria	exist,	the	entry	criteria	
were	not	consistent	across	trials.		
All	trials	compared	artesunate	with	quinine,	but	only	three	administered	both	
artesunate	and	quinine	using	the	current	recommended	dosing	schedules	
(artesunate:	2·4	mg/kg	on	admission,	at	12	hours,	at	24	hours,	and	then	once	daily	
until	starting	oral	therapy;	quinine:	20	mg/kg	loading	dose,	then	10	mg/kg	every	8	
hours	until	starting	oral	therapy).		
Overall,	treatment	with	artesunate	significantly	reduced	the	risk	of	death	both	in	
adults	(RR	0.61,	95%	CI	0.50	to	0.75;	1664	participants,	five	trials;	high	quality	
evidence)	and	children	(RR	0.76,	95%	CI	0.65	to	0.90;	5765	participants,	four	trials;	
high	quality	evidence)	(see	Figure	8).	
In	children,	treatment	with	artesunate	was	associated	with	an	increase	in	the	
incidence	of	neurological	sequelae	at	the	time	of	hospital	discharge	(RR	1.41,	95%	
CI	1.05	to	1.88;	6422	participants,	three	trials).	
However,	one	trial	followed	participants	up	until	day	28	to	see	if	these	sequelae	
resolved.	Of	the	170	children	with	sequelae	at	the	time	of	discharge,	129	(75.9%)	
were	available	for	assessment	on	day	28,	and	68	of	these	(52.7%)	had	fully	
recovered.	At	this	time	point	the	difference	between	groups	was	not	statistically	
significant	(RR	1.23,	95%	CI	0.74	to	2.03;	4857	participants,	one	trial).	
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Figure	8:	Forest	plot	of	randomized	trials	comparing	artesunate	with	quinine	for	the	primary	outcome:	death.	
Taken	from	Sinclair	2012.	[2]	
	
Strengths	and	limitations	of	this	approach	
This	review	provided	clear	evidence	that	artesunate	was	superior	to	quinine	at	
reducing	deaths,	and	in	the	conclusions	we	went	as	far	as	stating	that	further	trials	
comparing	these	two	anti-malarials	in	the	general	population	were	unnecessary	[2].	
The	result	appeared	applicable	to	all	populations	and	settings,	and	consequently	
the	decision	about	whether	to	change	a	national	first-line	policy	from	quinine	to	
artemether	shifted	to	other	considerations.	
In	a	minor	update	in	2012,	we	added	a	brief	appraisal	of	the	cost-effectiveness	of	
artesunate	versus	quinine.	Following	a	formal	search	we	identified	two	cost-
effectiveness	studies	conducted	alongside	the	two	large	multicentre	efficacy	trials	
[48][49].	Based	on	a	number	needed	to	treat	of	41	(taken	from	the	large	
multicentre	trial	in	children),	switching	to	artesunate	was	estimated	to	cost	$123	
per	additional	life	saved;	a	highly	cost-effective	intervention	by	any	standard	[50].		
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However,	later	that	year	during	a	collaborative	project	with	the	Medicines	for	
Children	Project,	the	WHO	Essential	Medicines	Department,	and	the	Ghana	
National	Drugs	Programme,	we	encountered	unexpected	problems	when	
reconsidering	the	evidence	for	the	Ghanaian	national	context	[5].	
Firstly,	it	was	noted	that	artemether	(an	alternative	artemisinin	derivative	to	
artesunate	but	with	less	favourable	pharmacokinetics)	had	entered	common	use	in	
Ghana	due	to	its	widespread	availability	and	ease	of	use.	Neither	the	Cochrane	
review	nor	the	WHO	guideline	had	commented	on	the	comparative	effects	of	
artesunate	and	artemether.	To	appropriately	consider	artesunate	as	a	first-line	
treatment	in	Ghana,	the	national	committee	therefore	tasked	a	small	team	to	
utilize	evidence-based	approaches	to	appraise	and	summarize	older	non-Cochrane	
systematic	reviews	of	artemether	versus	artesunate	and	artemether	versus	quinine	
[11].		
Secondly,	and	perhaps	more	importantly,	there	were	major	problems	with	the	
feasibility	of	rapid	policy	change.	There	remained	a	worldwide	shortage	of	
artesunate,	and	the	committee	was	rightly	concerned	about	the	potential	for	
programmatic	harms	with	a	change	from	a	drug	with	a	reliable	supply	chain	
(quinine)	to	one	with	an	unreliable	supply	and	a	need	to	quality-assure	the	product	
(due	to	the	widespread	problem	of	fake	anti-malarials	in	Ghana).	
The	artesunate	review,	the	WHO	recommendation,	and	the	subsequent	
consideration	by	the	Ghana	National	Drugs	Programme	demonstrated	the	
importance	of	national	debate	before	implementing	WHO	recommendations	(even	
with	strong	recommendations	based	on	high	quality	evidence).	In	this	instance,	
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guideline	development	at	a	national	level	influenced	subsequent	recommendations	
at	the	global	level.	
Influence	on	WHO	recommendations	
The	updated	review	was	presented	to	the	WHO	panel	in	March	2011,	and	after	
consideration	artesunate	was	recommended	as	first	line	treatment	for	all	age	
groups	worldwide	(Strong	recommendation,	high	quality	evidence).		
Subsequent	to	this,	and	in	response	to	our	work	in	Ghana,	I	supported	and	advised	
a	new	review	team	to	conduct	a	Cochrane	review	of	artemether	for	treating	severe	
malaria	[10].	This	review	was	presented	to	the	WHO	panel	in	2014,	and	artemether	
was	recommended	in	preference	to	quinine	when	artesunate	was	unavailable	
(Conditional	recommendation,	low-quality	evidence).
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Chapter	4.	Which	diagnostic	approach	for	malaria?	
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Background	
The	gold	standard	for	malaria	diagnosis	is	confirmation	of	the	presence	of	malaria	
parasites	in	a	symptomatic	person’s	blood	by	light	microscopy	[51].	However,	most	
malaria	episodes	and	deaths	occur	in	rural	parts	of	Africa	where	light	microscopy	is	
difficult	to	implement	and	maintain.	Consequently,	prior	to	the	development	and	
availability	of	Rapid	Diagnostic	Tests	(RDTs)	the	WHO	recommended	a	pragmatic	
approach	labelled	‘presumptive	treatment	for	malaria’,	whereby	all	children	with	
fever	were	given	anti-malarials	regardless	of	the	presence	or	absence	of	alternative	
causes	for	their	fever	[52][53].		
This	presumptive	approach	accepted	the	substantial	overuse	of	anti-malarials	
because	the	available	mono-therapies	were	cheap	and	well	tolerated.	However,	the	
increased	cost	associated	with	artemisinin-based	combination	therapies	and	the	
declining	malaria	prevalence	in	many	settings	raised	the	relative	importance	of	
diagnosing	and	treating	other	causes	of	fever	[54][55].	
From	a	health	systems	perspective	RDTs	have	the	potential	to	substantially	reduce	
the	over-prescription	of	anti-malarial	drugs	by	reducing	the	misclassification	of	
fevers,	especially	in	low-prevalence	areas	[56][57].	Consequently,	in	2010,	the	WHO	
recommended	a	switch	from	presumptive	treatment	to	parasitological	diagnosis	for	
all	[30],	and	promoted	this	new	strategy	as	a	way	to	improve	the	care	of	people	
with	malaria	[58].	
However,	a	simple	logic	model	demonstrates	that	people	with	malaria	are	only	
likely	to	be	harmed	by	the	introduction	of	RDTs,	as	a	small	number	will	be	
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misclassified	as	not	having	malaria	(false	negatives)	and	the	appropriate	anti-
malarial	will	be	withheld	or	delayed	(see	figure	9).	Instead,	the	potential	health	
benefits	of	introducing	RDTs	are	restricted	to	people	whose	fever	is	not	due	to	
malaria,	for	whom	a	negative	RDT	result	should	prompt	the	health	worker	to	look	
for	and	treat	the	true	cause	of	their	fever.		
Figure	9:	Logic	framework	for	modeling	the	effect	on	health	outcomes	of	introducing	RDT-supported	
diagnosis	compared	to	clinical	diagnosis	alone.	Taken	from	Odaga	2014.	[3]	
	
We	therefore	undertook	a	review	of	RDT-assisted	diagnosis	versus	presumptive	
treatment	to	establish	the	relative	benefits	and	harms	of	introducing	RDTs.		
Policy	question	
Does	the	introduction	of	Rapid	Diagnostic	Tests	(RDTs)	into	algorithms	for	
diagnosing	and	treating	people	with	fever	improve	health	outcomes,	and	reduce	
anti-malarial	prescribing?	
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Methods	
We	followed	standard	Cochrane	methods	to	search	for,	appraise,	and	synthesize	
individual	and	cluster	randomized	trials	comparing	RDT-supported	algorithms	with	
algorithms	using	clinical	diagnosis	alone.		
The	primary	outcomes	were:	the	proportion	of	patients	still	unwell	at	follow-up,	
and	the	proportion	of	patients	with	fever	prescribed	anti-malarials.	Secondary	
outcomes	were:	the	proportion	of	patients	with	fever	prescribed	antibiotics,	the	
proportion	of	microscopy-positive	patients	not	prescribed	anti-malarials,	and	the	
proportion	of	microscopy-negative	patients	prescribed	anti-malarials.	
In	reviews	of	complex	interventions	such	as	this,	clear	descriptions	of	the	
intervention	are	essential	to	understanding	the	applicability,	and	feasibility,	of	
achieving	the	same	results	outside	of	a	trial	setting.	In	this	review	we	presented	this	
information	in	additional	tables	(see	figure	10),	and	these	were	used	to	guide	our	
investigation	of	heterogeneity,	and	assessments	of	directness	and	applicability.	The	
tables	summarize	details	of	the	epidemiological	setting,	the	training	provided	to	
health	staff,	and	the	protocols	used	to	guide	treatment	for	those	testing	positive	
and	negative.	
We	used	the	GRADE	approach	to	evaluate	the	quality	of	evidence,	and	presented	
the	effect	estimates	for	the	main	outcomes	alongside	the	GRADE	judgments	in	
summary	of	findings	tables.	
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Key	findings	
We	included	seven	trials,	enrolling	17505	people	with	fever	or	reported	history	of	
fever;	two	individually	randomized	trials	and	five	cluster-randomized	trials.	All	trials	
were	conducted	in	rural	African	settings.		
In	most	trials	the	health	workers	diagnosing	and	treating	malaria	were	nurses	or	
clinical	officers	with	less	than	one	week	of	training	in	RDT-supported	diagnosis.	
Health	worker	prescribing	adherence	to	RDT	results	was	highly	variable:	the	
number	of	participants	with	a	negative	RDT	result	who	received	anti-malarials	
ranged	from	0%	to	81%.		
Overall,	RDT-supported	diagnosis	had	little	or	no	effect	on	the	number	of	
participants	remaining	unwell	at	four	to	seven	days	after	treatment	(6990	
participants,	five	trials;	low	quality	evidence);	but	using	RDTs	reduced	prescribing	of	
anti-malarials	by	up	to	three-quarters	(17287	participants,	seven	trials;	moderate	
quality	evidence).	As	would	be	expected,	the	reduction	in	anti-malarial	prescriptions	
was	highest	where	health	workers’	adherence	to	the	RDT	result	was	high,	and	
where	the	true	prevalence	of	malaria	was	lower	(see	figure	10).	
Using	RDTs	to	support	diagnosis	did	not	have	a	consistent	effect	on	the	prescription	
of	antibiotics,	with	some	trials	showing	higher	antibiotic	prescribing	and	some	
showing	lower	prescribing	in	the	RDT	group	(13573	participants,	five	trials;	very	low	
quality	evidence).		
One	trial	reported	malaria	microscopy	on	all	enrolled	patients	in	an	area	of	
moderate	endemicity,	so	we	could	compare	the	number	of	patients	in	the	RDT	and	
clinical	diagnosis	groups	that	actually	had	microscopy-confirmed	malaria	infection	
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but	did	not	receive	anti-malarials.	No	difference	was	detected	between	the	two	
diagnostic	strategies	(1280	participants,	one	trial;	low	quality	evidence).		
		
Figure	10:	Table	of	characteristics	of	interventions	in	trials	comparing	RDT-supported	diagnosis	with	clinical	
diagnosis	alone.	Modified	from	Odaga	2014.	[3]	
Characteristic	 Trial	ID	
Ansah	2010	 Bisoffi	2009	 Yeboah-Antwi	
2010	
Skarbinski	2009	
Training	
Who	was	trained	to	follow	
the	RDT	algorithm?	
Nurses	and	
nurse	
assistants	
Nurses	 Community	
health	
workers	
Drs,	nurses,	and	
clinical	officers	
Who	conducted	the	
training?	
Nurses,	after	a	
training	
course	
Not	described	 Experienced	
IMCI	trainers	
Nurses	after	a	
two-week	
course	
How	long	was	the	training?	
(days)	
2	 3	 5	 Half-day	
Was	a	written	guideline	
provided?	
Unclear	 Unclear	 Unclear	 Yes	
What	supervision	was	
conducted?	
Unclear	 Unclear	 Record	review	
and	feedback	
(monthly)	
Observation	
and	feedback		
(once,	2-months	
after	training)	
Were	staff	incentives	
provided?	
No	 No	 Bicycles	 No	
Who	conducted	the	RDT	
tests?	
Research	staff	 Research	staff	 Prescribers	 Prescribers	
Which	RDT-type	was	used?	 OptiMAL-IT	
(pLDH)	
Paracheck	
(HRP-2)	
ICT	malaria	Pf	
(HRP-2)	
Paracheck	(HRP-
2)	
Were	the	RDTs	provided	
free?	
Yes	 Yes	 Yes	 Yes	
Were	the	anti-malarials	
provided	free?	
Yes	 Yes	 Yes	 Yes	
Were	the	antibiotics	
provided	free?	
Yes	 Yes	 Yes	 Yes	
Algorithm	
Test	all	cases	of	fever	with	
RDTs?	
Yes	 Yes	 Yes	 Yes	
Prescribe	only	if	RDT	
positive?	
Yes	 Yes	 Yes	 Yes	
Do	not	prescribe	if	RDT	is	
negative?	
Yes	 Yes	 Yes	 Yes	
Management	of	RDT-
negative	cases?	
Not	described	 Look	for	other	
causes	and	
treat	as	per	
STG	
Amoxicillin	if	
signs	of	
pneumonia;	
else	refer	
Not	described	
Guidance	on	prescribing	
antibiotics?	
Not	
mentioned	
Not	
mentioned	
Not	
mentioned	
If	pneumonia	is	
suspected	
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Figure	11:	Forest	plot	of	randomized	trials	comparing	RDT-supported	diagnosis	with	clinical	diagnosis	alone	
for	the	outcome:	anti-malarial	prescriptions.	Taken	from	Odaga	2014.	[3]	
	
Strengths	and	limitations	of	this	approach	
The	GRADE	approach	to	appraising	diagnostic	tests	remains	in	development	and	
has	not	yet	been	formally	adopted	by	the	Cochrane	Collaboration	[59].	However,	
the	approach	emphasizes	the	importance	of	questioning	whether	the	introduction	
of	a	new	diagnostic	test	actually	improves	patient-important	outcomes,	and	the	
most	direct	way	to	evaluate	this	is	through	a	randomized	comparison	of	two	
diagnostic	strategies.	That	was	the	approach	taken	in	this	systematic	review.		
The	alternative	is	to	model	clinical	outcomes	using	the	sensitivity	and	specificity	of	
the	test,	provided	by	a	systematic	review	of	diagnostic	test	accuracy	[60],	and	
evidence-based	predictions	of	what	will	happen	to	those	testing	false	positive,	true	
positive,	true	negative	and	false	negative;	i.e.	who	will	benefit	and	who	will	be	
harmed.	We	presented	this	approach	in	the	background	to	the	review	alongside	the	
conceptual	framework	(figure	9).		
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Our	systematic	review	demonstrated	clearly	that	even	with	fairly	minimal	training,	
the	introduction	of	RDTs	substantially	reduces	unnecessary	prescriptions	of	anti-
malarials	(see	figure	11);	an	important	consideration	from	a	health	system	
perspective.	However,	the	review	provided	only	limited	reassurance	to	health	
workers	and	patients	that	this	did	not	result	in	a	substantial	increase	in	adverse	
health	outcomes.	The	included	trials	missed	the	opportunity	to	demonstrate	health	
benefits	by	concentrating	follow-up	care	on	those	testing	positive	for	malaria,	
rather	than	those	testing	negative	(the	only	group	who	are	likely	to	benefit	or	be	
harmed).	While	all	trials	gave	a	clear	description	of	the	subsequent	care	of	people	
testing	positive,	very	little	detail	was	provided	on	what	would	happen	to	those	who	
tested	negative;	there	was	little	or	no	description	of	when	a	test	would	be	
repeated,	of	what	protocols	would	be	utilized	to	look	for	alternative	causes,	or	of	
when	and	how	antibiotics	would	be	used.		
In	our	follow-up	paper	in	the	British	Medical	Journal,	we	highlighted	and	discussed	
some	of	these	key	questions,	and	it	seems	likely	that	the	evidence	to	reassure	
health	staff	and	patients	will	not	come	from	randomized	trials	[12].	In	an	ideal	
world,	local	audits	would	provide	feedback	to	health	workers	on	the	proportion	of	
false	negative	results	in	their	setting	(by	conducting	studies	of	parallel	RDT	and	
microscopy	testing),	and	on	the	subsequent	clinical	course	of	those	discharged	
home	without	anti-malarials.	However,	in	reality	these	audits	will	probably	be	
conducted	as	observational	cohort	studies	due	to	the	lack	of	routine	data	collection	
in	these	settings,	and	we	found	one	published	example	of	this	from	Tanzania	[61].	
Researchers	tracked	1000	children	for	two	weeks	after	attending	health	services	
with	a	fever,	and,	reassuringly,	patients	with	negative	RDT	results	seemed	to	re-
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present	to	health	services	if	they	failed	to	get	better,	and	there	were	no	recorded	
instances	of	malaria-related	deaths	in	people	discharged	home	without	anti-
malarials.	This	result	is	probably	only	generalizable	to	settings	with	similar	access	to	
healthcare	services	(geographically	and	financially),	and	further	similar	studies	
would	help	guide	future	recommendations.		
Influence	on	WHO	recommendations	
The	results	of	the	review	were	presented	to	the	WHO	MTG	committee	in	October	
2014.	However,	to	date	the	committee	has	been	reluctant	to	make	specific	
recommendations	around	the	use	of	diagnostic	tests,	and	instead	simply	makes	a	
good	practice	statement	that	‘the	diagnosis	should	be	confirmed	parasitologically	
prior	to	treatment’	[30].		
In	future	editions	of	the	guideline,	evidence-based	approaches	could	be	used	to	
make	statements	about:	
• When	to	do	a	rapid	diagnostic	test	–	the	clinical	criteria	that	should	initiate	
testing	in	specific	epidemiological	settings.		
• When	to	repeat	a	test	–	the	clinical	criteria	for	re-testing.	
• When	to	treat	presumptively	-	the	epidemic	threshold	for	reverting	to	
presumptive	treatment	due	to	a	shift	in	the	balance	of	benefits	and	harms	
(and	cost-utility)	of	testing.	
• Interventions	to	improve	adherence	to	test	results.
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Chapter	5.	Facilitating	national	guideline	development	
Main	papers	
Sinclair	D,	Isba	R,	Kredo	T,	Zani	B,	Garner	P.	World	Health	Organization	guideline	
development:	an	evaluation.	PLoS	ONE.	2013;8(5):e63715.	[4]	
Sinclair	D,	Gyansa-Lutterodt	M,	Asare	B,	Koduah	A,	Andrews	E,	et	al.	Integrating	
global	and	national	knowledge	to	select	medicines	for	children:	the	Ghana	National	
Drugs	Programme.	PLoS	Medecine.	2013;10(5):e1001449.	[5]	
Additional	contributing	work	
Sinclair	D,	Garner	P.	Annex	to	the	World	Health	Organization	malaria	treatment	
guidelines:	Grading	of	Recommendations	Assessment,	Development	and	Evaluation	
(GRADE)	for	assessing	the	quality	of	evidence.	[14]	
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Background	
An	internal	evaluation	of	WHO	guidelines	in	2003	was	never	published	but	is	
reported	to	have	found	that	‘most	WHO	guidelines	did	not	meet	most	of	the	AGREE	
criteria’	[62].	The	assumption	was	that	although	the	organization	had	internal	
guidance	for	the	development	of	recommendations,	it	was	rarely	followed	[63][64].	
To	investigate	this,	Oxman	and	colleagues	conducted	in-depth	interviews	with	
senior	staff	about	the	processes	they	used	to	formulate	recommendations	and	
published	the	results	in	the	Lancet	in	2007.	While	there	was	variation	between	
departments,	most	described	a	process	of	expert	consensus	without	any	formal	
collation,	appraisal,	or	consideration	of	evidence	[62].	
In	response	to	this	public	criticism,	the	WHO	moved	quickly	to	strengthen	guideline	
processes	within	the	institution	[65].	A	guideline	review	committee	(GRC)	was	
established	and	tasked	with	overseeing	the	implementation	of	evidence-based	
processes,	and	the	GRADE	approach	to	formulating	recommendations	was	formally	
adopted	[66].	
In	2011,	in	response	to	a	request	from	the	WHO	GRC,	we	undertook	a	re-evaluation	
of	WHO	guidelines	and	guideline	processes	to	look	for	and	document	any	changes	
following	the	introduction	of	stricter	quality	control	and	the	implementation	of	the	
GRADE	approach.	Also	in	2011,	we	conducted	a	separate	pilot	project	in	Ghana,	
which	provided	insights	into	the	applicability	and	usability	of	global	
recommendations.		
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Policy	questions	
Has	the	quality	of	WHO	guidelines	improved	since	the	formation	of	the	GRC,	and	
what	are	the	experiences	and	perceptions	of	WHO	departments	about	the	
implementation	of	GRADE?	
Methods	
For	the	evaluation	of	WHO	guidelines,	we	utilized	a	matched	before-and-after	study	
design	to	compare	10	guidelines	published	in	2010	(from	a	spread	of	WHO	
departments	and	across	a	range	of	broad	topic	areas)	with	10	guidelines	published	
before	the	GRC	(earlier	versions	of	the	same	guideline	where	possible).	We	used	
the	AGREEII	appraisal	tool	to	assess	the	methods	and	presentation	of	each	
guideline	[22].	We	then	interviewed	senior	staff	from	18	WHO	departments	about	
their	approaches	to	formulating	recommendations,	and	their	experiences	with	the	
GRC	and	the	application	of	the	GRADE	approach.		
In	Ghana,	working	with	the	WHO	Essential	Medicines	Department,	we	identified	
five	paediatric	medicines	that	were	strongly	recommended	by	the	WHO	for	low-
income	countries	such	as	Ghana,	but	were	not	yet	adopted	onto	the	Ghana	
essential	medicines	list.	We	then	trained	local	Ministry	of	Health	staff	to	retrieve,	
appraise,	and	interpret	systematic	reviews,	and	prepare	evidence	summaries	
utilizing	the	structure	developed	by	the	SUPporting	POlicy	relevant	Reviews	and	
Trials	(SUPPORT)	project	[67].	These	summaries	included	appraisals	of	the	benefits	
and	harms,	the	potential	public	health	impact,	costs,	and	feasibility	of	introducing	
each	drug	in	Ghana,	and	were	used	to	facilitate	informed	decision-making	by	the	
national	expert	committee	in	November	2011.		
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Key	findings	
We	found	marked	improvements	in	GRC-approved	guidelines,	with	average	scores	
higher	across	all	six	AGREE	domains	compared	with	pre-GRC	guidelines.	The	biggest	
improvements	were	noted	for	‘rigor	of	development’	(up	37.6%,	from	30.7%	to	
68.3%)	and	‘editorial	independence’	(up	52.7%,	from	20.9%	to	73.6%):	both	
important	markers	of	quality	and	reliability.		
‘Stakeholder	involvement’	and	‘applicability’	were	now	the	lowest-scoring	domains	
in	GRC-approved	guidelines,	and	these	are	probably	the	most	difficult	to	do	well	at	
a	global	level.	Indeed,	many	of	the	interviewees	acknowledged	that	making	
recommendations	that	were	intended	to	inform	policies	in	many	different	settings	
was	not	straightforward.	There	was	uncertainty	about	how	to	incorporate	
considerations	about	disease	burden,	health	infrastructure	and	financing,	and	
cultural	values	and	preferences	into	WHO	documents,	or	how	to	provide	the	
necessary	contextual	guidance	within	the	framework	of	existing	methods.		
This	finding	was	further	borne	out	in	Ghana,	where	applying	global	
recommendations	was	not	straightforward	for	any	of	the	medicines,	regardless	of	
the	presence	or	absence	of	high-quality	evidence	of	important	clinical	benefits.		
Our	experience	across	the	five	topics	identified	four	factors	that	generated	debate	
and	uncertainty	in	the	committee:		
1) The	available	trials	were	primarily	conducted	in	non-African	settings,	with	
plausible	reason	to	doubt	the	effect	could	be	generalized	(for	example,	zinc	
sulphate	for	acute	diarrhoea	in	children);		
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2) The	trials	used	control	groups	which	did	not	reflect	current	practice	in	
Ghana	(for	example,	trials	of	artesunate	compared	it	with	quinine	but	in	
Ghana	artemether	was	widely	used);		
3) Evidence	on	cost	and	cost-effectiveness	was	unavailable	(for	zinc	sulphate,	
chlorhexidine,	caffeine	citrate,	and	dispersible	amoxicillin);	and		
4) Reliable	suppliers	were	either	limited	or	not	immediately	available	(all	five	
medicines).	
Strengths	and	limitations	of	this	approach	
For	the	past	decade,	much	of	the	focus	on	WHO	guideline	development	has	been	
around	improving	the	transparency	and	reliability	of	the	methods	[62][63][65].	Our	
appraisal	of	WHO	guidelines	demonstrated	unequivocally	that	improvements	had	
been	made.	Even	without	any	tests	for	statistical	significance,	the	improvements	
were	large	and	obvious,	and	subsequent	WHO	guideline	appraisals	have	confirmed	
this	[68][69].	
Moving	forward,	these	two	papers	highlighted	the	difficulty	and	importance	of	
addressing	applicability	in	global	guidance	(and	systematic	reviews).	The	Ghana	
project	in	particular	demonstrated	that	a	statement	that	a	recommendation	was	
based	on	high	quality	evidence	at	a	global	level	was	not	enough	to	facilitate	
confident	decision-making	at	the	national	level.	The	Ghana	committee	rightly	
wanted	to	know	how	the	trial	populations	and	settings	(and	control	groups)	related	
to	their	own,	and	this	has	implications	for	the	future	presentation	of	both	
systematic	reviews	and	guidelines.		
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As	an	example	of	this,	the	Ghana	national	committee	considered	the	WHO	
recommendation	for	zinc	supplementation	during	acute	diarrhoea	in	low-	and	
middle-income	countries	[70].	The	Cochrane	review	available	at	the	time	concluded	
that:	‘In	areas	where	diarrhoea	is	an	important	cause	of	child	mortality,	research	
evidence	shows	zinc	is	clearly	of	benefit	in	children	aged	six	months	or	more’	[71].	
However,	the	analysis	sub-grouped	by	continent	presented	in	figure	12	
demonstrates	that	almost	all	of	the	evidence	for	an	effect	on	diarrhoea	duration	is	
from	Asian	studies,	and	the	only	African	study	to	date	failed	to	demonstrate	an	
effect.	This	was	problematic	for	the	committee	in	Ghana,	especially	as	there	were	
good	reasons	to	suspect	that	the	effects	of	zinc	vary	by	location	dependent	on	the	
local	diet	and	risk	of	zinc	deficiency;	the	coastal	populations	in	Ghana	eat	a	lot	of	
fish	and	are	therefore	unlikely	to	be	zinc-deficient	[72].	
Traditionally,	sub-group	analyses	are	presented	in	Cochrane	reviews	where	they	
have	been	used	to	explore	and	explain	statistical	heterogeneity.	However,	they	
have	become	a	key	part	of	the	GRADE	assessment	of	‘directness’	or	applicability,	
and	facilitate	interpretation	of	the	review	regardless	of	the	presence	or	absence	of	
statistical	heterogeneity.				
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Figure	12:	Forest	plot	of	zinc	supplementation	versus	placebo	for	the	outcome:	duration	of	diarrhoea.	
Adapted	from	Lazzerini	2008.	[71]	
	
For	global	guideline	developers	this	implies	a	need	to	pre-specify	which	factors	
might	influence	the	effectiveness	of	an	intervention	and	reduce	applicability,	and	to	
formally	consider	each	of	these	alongside	each	recommendation;	explicitly	stating	
where	an	effect	has	been	proven,	where	it	remains	uncertain,	and	the	plausible	
reasons	why	it	may	be	more	or	less	effective	in	these	scenarios.	Indeed,	these	steps	
are	explicitly	recommended	by	the	GRADE	working	group	[73][74].	For	infectious	
diseases,	background	resistance	would	obviously	be	important	(and	time	and	place	
might	be	used	as	surrogate	markers),	but	many	other	factors	such	as	age,	disease	
prevalence,	or	nutritional	status	might	also	be	important.	
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Influence	on	WHO	recommendations	
The	results	of	the	WHO	guideline	evaluation	were	presented	to	a	cross-
departmental	meeting	of	the	WHO	in	Geneva	in	November	2012.	Informal	feedback	
from	the	GRC	credits	the	paper	with	helping	to	strengthen	the	commitment	of	the	
organization	to	the	improved	standards,	and	reinforcing	the	authority	of	the	GRC.	
The	findings	of	the	Ghana	paper	were	presented	at	a	WHO	meeting	of	the	Essential	
Medicines	for	Children	Project	(November	2011),	and	at	the	Cochrane	Colloquium	
in	Hyderabad	(September	2014).	This	paper	highlights	the	importance	of	national	
debate	of	the	evidence-base	and	implications	of	policy	change,	prior	to	adopting	
and	implementing	global	recommendations,	and	fits	within	a	broader	discussion	of	
the	importance	of	documenting	the	steps	between	evidence	and	decisions.		
The	GRADE	working	group	(through	an	extension	project	known	as	DECIDE:	
Developing	and	Evaluating	Communication	strategies	to	support	Informed	
Decisions	and	practice	based	on	Evidence),	has	now	developed	worksheets	for	use	
by	guideline	panels,	to	formally	document	the	evidence	and	debate	around	each	of	
the	different	factors	influencing	a	decision:	size	of	the	problem,	benefits	and	harms	
of	the	intervention,	costs,	feasibility,	acceptability	etc.	[75].		
In	the	third	edition	of	the	WHO	Malaria	Treatment	Guidelines	we	included	a	
simplified	version	of	this	worksheet	(which	captured	some	of	the	important	factors	
influencing	the	decisions)	but	the	panel	did	not	openly	discuss	each	of	the	
considerations	in	a	step-wise	fashion	as	advocated	by	the	GRADE	group	[14].	
Although	the	current	textbook	format	of	the	Malaria	Treatment	Guidelines	seems	
popular	with	end	users	(it	is	a	bestseller	among	WHO	documents),	future	editions	
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might	better	serve	the	information	needs	of	malaria	programme	managers	if	they	
utilized	this	worksheet	approach	to	clearly	document	the	rationale,	evidence,	and	
debate	around	each	major	recommendation.	
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Chapter	6.	Conclusions	
This	PhD	presents	a	case	study	of	an	academic	group	working	as	info-mediaries	at	
the	interface	between	research	and	global	policy,	and	at	the	interface	between	
global	policy	and	national	decisions:	advising	on	methodological	issues,	conducting	
systematic	evidence	reviews	in	response	to	information	needs,	and	developing	
approaches	to	reinterpret	reviews	for	national	decision-making.	
It	contains	one	of	the	very	few	formal	evaluations	of	policy	making	within	the	WHO,	
and	the	first	published	demonstration	of	evidence-based,	rigorous,	processes	being	
used	to	re-assess	global	recommendations	for	a	specific	low-income	setting.	The	
included	systematic	reviews	facilitated	new,	transparent,	global	recommendations	
for	dihydroartemisinin-piperaquine	as	a	first	line	therapy	for	uncomplicated	
malaria,	and	intravenous	artesunate	as	first-line	treatment	for	severe	malaria.		
The	scientific	contribution	of	this	work	
This	PhD	contributed	extensively,	particularly	in	the	field	of	malaria,	to	improved	
presentation	and	interpretation	of	systematic	review	results,	and	subsequently	to	
improved	transparency	in	global	and	national	level	recommendations.	The	included	
systematic	reviews	helped	to	establish	the	credibility	of	meta-analysis	in	the	
malaria	field,	and	were	among	the	first	to	include	innovative	elements	such	as:	
GRADE	summary	of	findings	tables,	standardized	language	reflecting	the	level	of	
certainty	in	effect	estimates,	logic	frameworks,	and	brief	economic	summaries.	My	
experiences	contributed	to	the	broader	discussions	on	these	topics	and	to	further	
development	of	their	methods	[77][78][79].	
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The	first	edition	of	the	WHO	Malaria	Treatment	Guidelines	recommended	five	drug	
combinations	but	stated	only	that	these	‘had	achieved	the	target	of	95%	treatment	
success’.	There	was	little	guidance	on	how	to	choose	between	these	five	
combinations,	and	little	comment	on	any	potential	adverse	effects.	Furthermore	
there	were	clear	inconsistencies	in	the	reporting	of	trial	results	across	malaria	
research	groups,	making	direct	comparison	between	trials	impossible.	
My	early	work,	summarizing	trial	data	for	artemisinin-based	combinations,	built	on	
existing	protocols	to	develop	a	standard	set	of	treatment	outcomes	(including	
adverse	effects),	and	a	standardized	approach	to	trial	analysis	that	fully	considered	
the	potential	effects	of	missing	data	on	the	primary	efficacy	outcomes.	These	were	
essential	for	the	credibility	of	meta-analysis	across	anti-malarial	drug	trials,	and	are	
now	standard	for	Cochrane	reviews	of	artemisinin-based	combination	therapies.	
To	facilitate	informed	national	drug	selection,	we	also	needed	to	provide	clear	
summaries	of	the	comparative	safety	of	the	main	ACTs.	We	therefore	developed	a	
system	for	assessing	the	completeness	of	adverse	event	monitoring	and	reporting,	
and	for	the	third	edition	of	the	malaria	treatment	guidelines	I	produced	detailed	
adverse	event	GRADE	profiles	for	each	ACT.		These	adverse	event	profiles	go	
beyond	any	current	guidance	of	either	Cochrane	or	the	GRADE	working	group,	and	
are	an	important	avenue	for	further	work.	Typically	health	staff	and	patients	
require	two	types	of	information	on	adverse	effects;	the	frequency	and	nature	of	
common	short	term	‘side-effects’:	for	which	there	is	now	a	reasonable	amount	of	
data	from	RCTs	of	ACTs;	and	the	risk	of	rare	but	serious	adverse	effects:	for	which	
RCTs	are	unlikely	to	be	sufficient.	In	a	forthcoming	review	of	mefloquine	to	prevent	
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malaria	in	travellers	we	have	further	developed	these	methods	to	incorporate	large	
amounts	of	data	from	non-randomized	studies	to	try	and	capture	data	on	rare	
effects	[80]	
My	work	in	Ghana	highlighted	the	importance	of	being	explicit	about	the	
applicability	of	systematic	review	results	if	they	are	to	be	truly	useful	to	decision-
makers	in	different	settings.	This	is	particularly	important	in	infectious	diseases	
where	resistance	(and	consequently	efficacy)	vary	with	time	and	place,	and	
geographical	presentations	of	data	were	essential	to	generating	confidence	among	
the	Ghana	national	guideline	panel.	Cochrane	methods	at	the	time	only	
recommended	sub-group	analysis	as	part	of	the	assessment	of	heterogeneity,	and	
applicability	was	usually	only	considered	informally	in	the	discussion.	To	improve	
this,	and	to	facilitate	decision	making	at	global	and	national	levels,	I	incorporated	
the	time	and	place	of	the	primary	trials	into	all	forest	plots,	and	conducted	sub-
group	analysis	against	a	pre-defined	set	of	applicability	criteria	regardless	of	the	
presence	or	absence	of	heterogeneity.	My	approach	was	developed	independently	
of	the	GRADE	working	group,	but	has	subsequently	been	recommended	as	part	of	
the	assessment	of	‘directness’	[81].		
Prior	to	the	development	of	the	GRADE	approach	to	assessing	the	quality	of	
evidence,	it	was	commonplace	for	the	conclusions	of	Cochrane	reviews	to	be	based	
solely	on	the	statistical	significance	of	the	primary	outcomes,	and	early	users	of	the	
GRADE	approach	often	saw	it	simply	as	an	additional	step	at	the	end	of	a	review.	
However,	the	real	value	of	the	GRADE	approach	is	its	ability	to	pull	together	all	the	
elements	of	a	Cochrane	review,	into	a	reliable	conclusion	that	fully	considers	the	
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risk	of	bias	of	the	trials,	the	characteristics	and	applicability	of	the	trials,	and	the	
statistical	certainty	in	the	results.	As	such,	applying	the	GRADE	approach	is	an	
integral	part	of	structuring	the	analysis,	writing	the	results,	and	drawing	
conclusions.	This	PhD	includes	the	first	two	reviews	by	the	Cochrane	Infectious	
Diseases	Group	to	contain	GRADE	summary	of	findings	tables,	and	these	reviews	
were	instrumental	in	establishing	these	processes	within	the	Cochrane	Infectious	
Diseases	group,	for	pushing	their	adoption	wider	in	the	collaboration,	and	for	
establishing	the	GRADE	approach	within	the	WHO	Malaria	Treatment	Guidelines.		
Alongside	the	adoption	of	GRADE,	these	reviews	also	pioneered	the	use	of	
standardized	wording	of	results,	especially	within	the	abstract	and	plain	language	
summaries	[82].	This	wording	was	developed	by	researchers	from	the	Cochrane	
EPOC	group,	and	aims	to	reflect	the	size	of	the	observed	effects	AND	the	overall	
confidence	that	this	effect	is	real	(the	GRADE	quality	of	the	evidence).	This	
innovation,	combined	with	the	formal	applicability	assessment,	and	GRADE	
assessment	of	the	quality	of	evidence,	combined	to	facilitate	transparent	and	
reliable	statements	about	the	results	of	systematic	reviews.	Subsequent	WHO	
recommendations	based	on	these	reviews	have	also	incorporated	language	
reflecting	both	the	estimated	magnitude	of	effects	and	the	certainty	in	these	
effects.		
Logic	frameworks	are	a	more	recent	addition	to	systematic	reviews,	which	require	
authors	to	think	critically	about	the	assumptions	underlying	a	research	question.	
They	can	be	used	to	clarify	the	proposed	mechanism	of	action	of	an	intervention,	
and	distinguish	the	important	impact	outcomes	from	the	intermediate	process	
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outcomes.	They	can	highlight	deficiencies	in	the	outcomes	being	measured	and	
reported	in	the	existing	trials,	and	contribute	to	improved	understanding.	The	logic	
framework	presented	within	this	PhD	helped	to	clarify	where	the	potential	benefits	
and	harms	of	introducing	RDTs	lay	(in	those	testing	negative),	and	in	what	
epidemiological	settings	the	benefits	and	risks	would	be	greatest.	These	insights	
had	not	been	clearly	articulated	in	any	policy	documents	at	the	time.	As	reviews	
begin	to	tackle	more	complex	questions,	logic	frameworks	are	likely	to	become	
increasingly	common	and	play	an	important	role	in	developing	the	question	and	
framing	the	interpretation.	During	the	course	of	this	PhD,	I	have	worked	with	
multiple	authorship	teams	to	develop	logic	frameworks	for	their	own	topic,	often	
leading	to	radical	restructuring	of	the	analyses	and	reframing	of	the	review	
conclusions.	These	reviews	have	helped	to	establish	logic	frameworks	within	the	
Cochrane	Infectious	Diseases	Group,	and	to	promote	their	use	wider	in	the	
collaboration.	
Cost	and	cost-effectiveness	are	usually	not	included	within	Cochrane	systematic	
reviews,	and	this	is	probably	appropriate	as	cost	only	becomes	relevant	once	the	
efficacy	and	safety	of	an	intervention	have	been	established.	Cost	considerations	
are	also	rarely	(or	only	briefly)	included	in	WHO	guidelines	(probably	due	to	rapid	
changes	and	variability	in	pricing).	The	evidence	for	the	clinical	superiority	of	
artesunate	in	severe	malaria	was	however	so	overwhelming	that	cost	(and	supply)	
became	the	primary	concern	for	national	policy-makers	following	the	WHO	
recommendation.	For	this	reason	I	supervised	the	inclusion	of	a	brief	summary	of	
economic	data	in	the	most	recent	update	of	this	review	(which	equates	to	a	very	
Chapter	6									52	
	
rapid	second	systematic	review	of	cost-effectiveness	data).	This	remains	one	of	the	
few	examples	of	this	methodology,	but	a	valuable	addition	to	this	review.		
The	developing	role	for	academics	at	the	interface	between	research	and	policy	
For	many	years,	‘getting	research	into	policy	and	practice’	was	an	elusive	and	
frustrating	problem	for	the	research	community,	but	over	the	last	20	years	
evidence	synthesis	has	grown	and	developed	to	fill	the	research-to-policy	gap.	
Subsequently,	the	development	of	the	GRADE	approach	has	provided	a	useable	
structure	for	converting	systematic	review	findings	into	transparent,	informed	
decisions.	
To	facilitate	and	strengthen	the	use	of	these	methods,	academic	input	is	now	
required	at	all	stages	of	the	guideline	process,	particularly	where	panels	are	heavily	
weighted	with	clinicians,	or	lack	sufficient	experience	in	research	synthesis.	It	is	
recognized	that	such	groups	may	struggle	to	formulate	clearly	answerable	
questions,	and	identify	where	and	how	evidence	synthesis	may	help	[66][76].			
Most	guideline	development	manuals	now	recommend	a	‘methodologist’	as	part	of	
a	guideline	panel,	but	very	little	has	been	written	about	the	required	competencies.	
The	WHO	guideline	for	guidelines	state	simply	that	the	methodologist	should	be	‘an	
expert	in	guideline	development	processes’	[66],	and	writing	in	the	Lancet	
prominent	members	of	the	GRADE	working	group	wrote	that	methodologists	
should	have	‘advanced	training	(usually	Masters	or	PhD)	in	clinical	epidemiology,	
and	extensive	experience	in	the	interpretation,	and	usually	the	generation,	of	new	
knowledge	from	clinical	research’	[83].	
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The	GRADE	and	DECIDE	methodologies,	though	logically	structured,	are	not	
straightforward	and	their	useful	application	requires	experience,	and	usually	
innovation	to	adapt	them	to	the	specific	circumstance.	To	achieve	this,	guideline	
methodologists	usually	require	not	only	the	obvious	experience	in	evidence	
synthesis	and	the	GRADE	approach,	but	also	a	diverse	group	of	skills	such	as	group	
facilitation,	consensus	building,	and	plain	language	writing.	
The	systematic	reviews	presented	within	this	PhD	were	primarily	developed	to	
contribute	to	the	development	of	the	WHO	Malaria	Treatment	Guidelines,	but	are	
equally	relevant	to	national	policy	decisions.	Consequently,	a	core	requirement	for	
national	policy	groups,	if	unnecessary	duplication	is	to	be	avoided,	will	be	the	ability	
to	reinterpret	or	adapt	systematic	reviews	developed	outside	of	their	own	guideline	
process.	As	in	my	work	in	Ghana,	this	may	involve	an	appraisal	of	the	systematic	
review	methods,	re-analysis	and	structuring	of	the	systematic	review	data	to	match	
the	local	question,	and	where	necessary	a	rapid	update	of	the	review.		
Our	experience	as	info-mediaries	
When	the	guideline	process	works	well,	evidence	synthesis	can	facilitate	discussion	
among	the	guideline	panel,	increase	confidence	in	decisions,	and	improve	the	
reliability	and	clarity	of	recommendations.	Indeed	this	PhD	presents	some	good	
examples	of	high	quality	research,	synthesized	in	high	quality	reviews,	leading	to	
unchallenged	and	clear	decisions.	The	underlying	principles	of	both	GRADE	and	
DECIDE	are	simple	and	logical,	and	easily	taught	to	inexperienced	panels.	
Inevitably	however,	the	process	is	rarely	this	straightforward,	even	with	more	
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experienced	panels.	Without	adequate	input	from	those	making	the	decisions,	
systematic	reviews	can	easily	ask	the	wrong	question,	or	the	right	question	in	the	
wrong	way.	Similarly,	without	sufficient	content	and	methodological	expertise,	
systematic	reviews	can	simply	fail	to	produce	useable	information	rendering	them	
useless	and	frustrating	to	the	panel.		
More	commonly	though,	systematic	reviews	are	criticized	for	taking	too	long	to	
produce,	or	failing	to	reach	a	definitive	conclusion	due	to	the	low	quality	evidence	
available	(and	therefore	being	a	waste	of	time	compared	to	expert	opinion).	High	
quality	systematic	reviews	take	time	to	produce	(often	up	to	two	years	unless	there	
are	authors	with	large	amounts	of	dedicated	time),	and	real	and	imagined	time	
pressures	(or	industry	pressures)	can	cause	experts	to	push	for	practice	change	long	
before	benefits	or	harms	have	been	reliably	demonstrated	in	clinical	trials.		
Within	the	world	of	evidence	synthesis,	there	has	been	much	talk	about	the	need	
for	‘rapid	reviews’	to	ensure	that	evidence	synthesis	meets	policy	windows.	In	our	
experience	however,	guideline	development	is	rarely	an	emergency,	and	important	
questions	can	usually	be	predicted	in	advance,	through	frequent	dialogue	with	
policy	makers,	and	regular	literature	searches.	Over	three	editions	of	the	malaria	
treatment	guidelines,	the	long-term	engagement	between	the	Cochrane	Infectious	
Diseases	Group	and	the	WHO	Malaria	Treatment	Guidelines	committee	(and	
independent	funding	to	complete	policy-relevant	malaria	reviews),	facilitated	
timely	evidence	synthesis	in	anticipation	of,	and	response	to,	emerging	questions.		
While	more	linkages	such	as	this,	between	academic	groups	and	guideline	groups,	
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should	be	encouraged,	where	possible	the	evidence	synthesis	itself	should	probably	
remain	independent	of	the	committee.	Throughout	our	involvement	with	the	WHO	
Treatment	Guidelines	Committee	we	sought	input	for	the	questions	and	the	
outcomes	of	interest,	and	on	occasion	invited	panel	members	to	peer	referee	draft	
reviews.	However,	we	usually	resisted	involvement	of	panel	members	on	review	
teams	as	this	can	compromise	their	freedom	to	challenge	prevailing	opinions	in	
light	of	the	evidence,	and	conversely	the	freedom	of	the	committee	to	challenge	
the	conclusions	and	interpretation	of	the	systematic	review.		
Systematic	reviews	are	often	perceived	as	rigid	or	mechanical,	with	defined	
methods	leading	to	a	set	outcome.	In	reality	though,	while	the	core	methods	are	
now	well	established,	and	the	GRADE	approach	has	added	a	structure	for	
formulating	conclusions	from	results,	there	remains	a	great	deal	of	freedom	in	both	
the	presentation	and	interpretation	of	the	summarized	evidence.	It	is	therefore	
helpful	if	methodologists	have	some	oversight	of	the	multiple	systematic	reviews	
(from	multiple	academic	teams),	required	for	a	single	guideline.	For	both	the	
Malaria	Treatment	Guidelines,	and	the	Ghana	evidence	summaries,	my	oversight	
enabled	standardization	of	outcomes	and	approaches	across	reviews,	which	in	turn	
facilitated	understanding	and	interpretation	by	the	guideline	panels.	Furthermore,	
it	is	not	unusual	for	guideline	groups	to	ask	more	focused	questions	after	seeing	the	
synthesized	evidence,	and	it	is	useful	to	have	access	to	the	datasets	to	respond	
quickly	to	such	questions	from	the	panels.		
There	are	also	frequently	tensions	between	mechanistic	logic	and	demonstrable	
evidence,	particularly	when	the	quality	of	the	evidence	summarized	by	a	systematic	
Chapter	6									56	
	
review	is	perceived	as	low	quality.	Evidence	synthesis	may	be	discounted	for	
providing	a	weak	answer	that	pulls	against	established	logic,	or	a	weak	answer	
when	a	strong	message	is	wanted.	Indeed	it	is	not	unusual	for	guideline	groups	to	
express	a	desire	for	strong	clear	messages,	whatever	the	evidence,	for	fear	of	being	
ignored,	or	uncertainty	that	those	enacting	the	recommendations	will	have	the	
ability	to	interpret	the	evidence	appropriately.		
Our	experience	in	Ghana	however,	was	the	opposite	of	this,	with	the	panel	adding	a	
layer	of	interpretation	to	both	high	and	low	quality	evidence	which	may	be	easily	
missed	at	a	global	level.	With	some	training	and	facilitation,	the	panel	(dominated	
by	clinicians)	quickly	understood	the	magnitude	and	certainty	in	research	findings	in	
favor	of	artesunate	for	severe	malaria	but	made	insightful	judgments	about	
potential	difficulties	with	implementation	and	the	undesirable	consequences	of	
this.	Similarly,	despite	the	obvious	limitations	in	both	the	applicability	and	feasibility	
of	the	evidence	for	chlorhexidine,	they	could	see	the	problems	with	current	
practice	and	the	benefits	of	further	local	research.	Rather	than	weakening	global	
recommendations,	these	insights	fed	back	into,	and	improved,	global	guidance.		
It	is	important	to	note	however,	that	these	insights	into	national	conditions	in	
Ghana	were	usually	informal,	based	simply	on	the	experiences	of	the	panel,	rather	
than	reliable	data.	Although	we	routinely	searched	for	national	data,	even	when	it	
existed,	the	panel	had	little	confidence	in	its	validity,	at	times	choosing	to	trust	the	
results	of	studies	conducted	elsewhere	rather	than	their	own	routine	data	
collection.	The	composition	of	the	panel	is	therefore	instrumental	in	gaining	diverse	
opinions,	and	the	DECIDE	frameworks	(or	SUPPORT	tools	we	utilized)	at	least	
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provide	a	transparent	and	structured	approach	for	considering	the	important	
factors.	
Preparing	global	guidelines	for	contextualization	at	national	level		
Moving	forward,	systematic	reviews	and	global	guidance	will	only	act	to	facilitate	
autonomous,	informed	decision-making	if	their	format	and	content	is	directly	
targeted	at	serving	the	information	needs	of	national	decision-makers.		
When	considering	the	evidence	of	effects	of	an	intervention,	there	is	a	need	for	
both	systematic	reviewers	and	guideline	groups	to	pre-specify	the	key	factors	that	
might	plausibly	influence	the	effects	in	a	given	population	or	setting;	to	adequately	
explore	this	effect;	and	to	clearly	present	the	findings	and	implications	[27][28][77].	
The	GRADE	criteria	of	consistency	and	directness	provide	a	framework	for	
considering	these	factors.		
Similarly,	for	complex	interventions	there	is	the	need	to	clearly	describe	all	facets	of	
the	interventions	with	the	potential	to	influence	the	outcome,	and	consider	the	
likelihood	that	real-life	(pragmatic)	interventions	will	really	achieve	these	aims.	As	
the	GRADE	approach	has	made	clear,	there	are	many	factors	that	influence	
decisions	beyond	evidence	of	effects.	The	GRADE/DECIDE	evidence-to-	decisions	
frameworks	go	some	way	to	increasing	the	transparency	of	these	additional	steps,	
by	presenting	both	the	evidence	and	debate	around	issues	such	as	cost	and	
feasibility.		
The	development	and	adoption	of	GRADE	summary	of	findings	tables,	and	DECIDE	
evidence-to-decision	frameworks,	has	radically	changed	the	format	and	content	of	
Chapter	6									58	
	
WHO	guidelines.	Moving	forward	it	would	be	invaluable	to	garner	feedback	from	
the	target-users	of	guidelines	on	the	usefulness	of	this	information,	the	clarity	of	
their	presentation,	and	the	influence	on	subsequent	national	decisions.		
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